Anika Therapeutics (ANIK) Stock Price, News & Analysis

Company Overview

Anika Therapeutics, Inc. is a global, fully integrated, and diversified orthobiologics company focused on the development, manufacture, and commercialization of novel therapies for orthopedic and tissue regeneration applications. Founded in 1998 and headquartered in Bedford, Massachusetts, Anika leverages its proprietary hyaluronic acid (HA) platform technology to create products designed to restore mobility, reduce pain and improve overall patient outcomes. The company’s core offerings include viscosupplementation injections for the treatment of osteoarthritis, surgical sealants, and aesthetic dermatology products.

In its viscosupplementation business, Anika markets products such as MONOVISC® and ORTHOVISC® which are used to alleviate knee pain associated with osteoarthritis by supplementing the synovial fluid in the joint. The surgical franchise includes HA-based bioadhesives and hemostats that support tissue repair and wound healing during soft tissue procedures. Additionally, the company has expanded its pipeline to include combination therapies, such as CINGAL®, which integrate HA with corticosteroids to provide both immediate pain relief and long-term joint health benefits.

With a commercial presence in over 25 countries, Anika continues to grow its global footprint through strategic partnerships and direct sales channels across North America, Europe, Latin America and select markets in Asia. The company’s manufacturing facilities in Bedford and Woburn, Massachusetts, are designed for scalable HA production and meet stringent regulatory standards, supporting both clinical development and commercial supply.

Under the leadership of President and CEO Atul Deshpande, Anika is committed to expanding its portfolio through targeted research and development initiatives aimed at next-generation orthobiologic solutions. The company’s strong focus on innovation, combined with an established commercial infrastructure, positions it to address growing demand for minimally invasive treatments in orthopedic, surgical and aesthetic medicine.

Key Stats

• Today's Range: $11.10 to $11.65
• 50-Day Range: $10.53 to $14.76
• 52-Week Range: $10.47 to $29.12
• Volume: 76,049 shs
• Average Volume: 76,030 shs
• Market Capitalization: $161.61 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.00
• Consensus Rating: Strong Buy

Anika Therapeutics Stock Analysis - MarketRank™

Anika Therapeutics scored higher than 86% of companies evaluated by MarketBeat, and ranked 144th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

Anika Therapeutics has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Anika Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Anika Therapeutics are expected to grow in the coming year, from ($0.84) to ($0.41) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Anika Therapeutics is -2.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Anika Therapeutics is -2.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Anika Therapeutics has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.08% of the float of Anika Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Anika Therapeutics has a short interest ratio ("days to cover") of 5.2.

Change versus previous month

Short interest in Anika Therapeutics has recently decreased by 3.09%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Anika Therapeutics does not currently pay a dividend.

Dividend Growth

Anika Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.7 / 5
• Environmental Score: -1.96

Percentage of Shares Shorted

3.08% of the float of Anika Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Anika Therapeutics has a short interest ratio ("days to cover") of 5.2.

Change versus previous month

Short interest in Anika Therapeutics has recently decreased by 3.09%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Anika Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.00 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Anika Therapeutics this week, compared to 2 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Anika Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.64% of the stock of Anika Therapeutics is held by insiders.

Percentage Held by Institutions

91.53% of the stock of Anika Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ANIK Stock Analysis - Frequently Asked Questions

How have ANIK shares performed this year?

Anika Therapeutics' stock was trading at $16.46 at the beginning of 2025. Since then, ANIK shares have decreased by 31.5% and is now trading at $11.27.

How were Anika Therapeutics' earnings last quarter?

Anika Therapeutics Inc. (NASDAQ:ANIK) announced its quarterly earnings results on Wednesday, March, 12th. The biotechnology company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.01) by $0.13. The biotechnology company had revenue of $30.60 million for the quarter, compared to analyst estimates of $29 million. Anika Therapeutics had a negative net margin of 41.28% and a negative trailing twelve-month return on equity of 7.22%.
Read the conference call transcript.

How do I buy shares of Anika Therapeutics?

Shares of ANIK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Anika Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Anika Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Advanced Micro Devices (AMD), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 3/12/2025
• Today: 7/12/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Health Care Supplies
• Current Symbol: NASDAQ:ANIK
• CIK: 898437
• Web: www.anikatherapeutics.com
• Phone: (781) 457-9000
• Fax: 781-305-9720
• Employees: 300
• Year Founded: 1992

Price Target and Rating

• Average Price Target for Anika Therapeutics: $20.00
• High Price Target: $21.00
• Low Price Target: $19.00
• Potential Upside/Downside: +77.5%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.88)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$56.38 million
• Net Margins: -41.28%
• Pretax Margin: -3.43%
• Return on Equity: -7.22%
• Return on Assets: -5.64%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.73
• Quick Ratio: 4.53

Sales & Book Value

• Annual Sales: $119.91 million
• Price / Sales: 1.35
• Cash Flow: $0.09 per share
• Price / Cash Flow: 123.50
• Book Value: $10.51 per share
• Price / Book: 1.07

Miscellaneous

• Outstanding Shares: 14,340,000
• Free Float: 12,959,000
• Market Cap: $161.61 million
• Optionable: Optionable
• Beta: 0.64